Pharmacological inhibition of ε-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure

Hypertension

Volumn 51, Issue 6, 2008, Pages 1565-1569

  Inagaki, Koichi ^a,b   Koyanagi, Tomoyoshi ^a   Berry, Natalia C ^a   Sun, Lihan ^a   Mochly Rosen, Daria ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OTSU RED CROSS HOSPITAL   (Japan)

Author keywords

Fibrosis; Heart failure; Hypertrophy; Protein kinase c; Ventricular remodeling

Indexed keywords

OLMESARTAN; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; V1-1 DELTA; V1-2 EPSILON; ANGIOTENSIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHANNELOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; ENZYME INHIBITION; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL; ANIMAL; CARDIOMEGALY; DRUG ANTAGONISM; DRUG COMBINATION; METABOLISM; PATHOLOGY; SALT INTAKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOMEGALY; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEART FAILURE; HYPERTENSION; IMIDAZOLES; MALE; PROTEIN KINASE C-EPSILON; RATS; RATS, INBRED DAHL; SODIUM CHLORIDE, DIETARY; TETRAZOLES;

EID: 45849091842     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.109637     Document Type: Article

References (15)

1. Inagaki K, Iwanaga Y, Sarai N, Onozawa Y, Takenaka H, Mochly-Rosen D, Kihara Y. Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. J Mol Cell Cardiol. 2002;34:1377-1385.
2. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol. 2002;39:1384-1391.
3. Sabri A, Steinberg SF. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem. 2003;251:97-101.
4. Dorn GW II, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc Natl Acad Sci USA. 1999;96:12798-12803.
5. Gu X, Bishop SP. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res. 1994;75:926-931.
6. Klein G, Schaefer A, Hilfiker-Kleiner D, Oppermann D, Shukla P, Quint A, Podewski E, Hilfiker A, Schroder F, Leitges M, Drexler H. Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. Circ Res. 2005;96:748-755.
7. Inagaki K, Begley R, Ikeno F, Mochly-Rosen D. Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide. Circulation. 2005;111:44-50.
8. Braun MU, Mochly-Rosen D. Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors. J Mol Cell Cardiol. 2003;35:895-903.
9. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Ann Rev Pharmacol Toxicol. 2005;45:657-687.
10. Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 1995;30:537-543.
11. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477:267-283.
12. Tobian L. Salt and hypertension. Lessons from animal models that relate to human hypertension. Hypertension. 1991;17:I52-I58.
13. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW II, Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. 2001;98:11114-11119.
14. Tanaka M, Terry RD, Mokhtari GK, Inagaki K, Koyanagi T, Kofidis T, Mochly-Rosen D, Robbins RC. Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation. 2004;110: II194-I199.
15. Koyanagi T, Noguchi K, Ootani A, Inagaki K, Robbins RC, Mochly-Rosen D. Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model. J Mol Cell Cardiol. 2007;43:517-522.